{"id":"W3088769124","doi":"10.1016/j.annonc.2020.08.2271","title":"LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":73,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Phases of clinical research; Lenvatinib; Clinical trial; Cancer; Gastroenterology; Sorafenib; Immunotherapy; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001227683,0.0002225298,0.0006035325,0.00007132188,0.00004256952,0.00000454909,0.0002575758,0.0001498628,0.00002288622],"category_scores_gemma":[0.0002064055,0.0002098915,0.00007860437,0.0001952507,0.0001068416,0.00000771431,0.0001827114,0.0001236882,0.000001957915],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003055331,"about_ca_system_score_gemma":0.0003517811,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001435788,"about_ca_topic_score_gemma":0.0005974889,"domain_scores_codex":[0.9983963,0.0001027399,0.0005703477,0.0004396904,0.0001534825,0.0003374336],"domain_scores_gemma":[0.9988349,0.00004524955,0.0004002047,0.0003082158,0.0002743576,0.0001370861],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1304086,0.06124668,0.2127303,0.0006228246,0.001813271,0.0002548645,0.0180503,0.02490219,0.2458698,0.000208833,0.02119274,0.2826996],"study_design_scores_gemma":[0.1395398,0.5159617,0.03510892,0.0001337832,0.0002809694,0.00001176728,0.002341894,0.000459258,0.2636385,0.00005014824,0.04134179,0.001131422],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972588,0.0003726186,0.00002214711,0.0003672845,0.00005710992,0.0007769638,0.00009065427,0.000007553539,0.00104691],"genre_scores_gemma":[0.9983749,0.0004259788,0.000120142,0.00072519,0.00006714787,0.00005494716,0.0001543581,0.00003143754,0.00004591643],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.454715,"threshold_uncertainty_score":0.8559128,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0351059942400495,"score_gpt":0.3413605588032494,"score_spread":0.3062545645631999,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}